Evercore ISI Group Initiates Coverage of TransMedics Group (TMDX) with Outperform Recommendation
Evercore ISI Group has initiated coverage of TransMedics Group (TMDX) with an "Outperform" rating. This new rating suggests that Evercore ISI analysts believe the company's stock is likely to perform better than the broader market or its sector.
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (NASDAQ:TMDX) securities. The investigation concerns whether the company and its officers engaged in corporate wrongdoing, specifically for investors who purchased shares prior to February 3, 2022, and continue to hold them. The firm encourages affected shareholders to contact them for more information and to assist with the investigation.
TransMedics group CFO Hernandez sells shares worth $1.12 million
TransMedics Group Inc. CFO Gerardo Hernandez sold shares totaling approximately $1.12 million on March 2nd and March 4th, while also exercising options to acquire shares worth $515,000. These transactions occurred as TMDX stock trades near its 52-week high after a 119% return over the past year. The company recently reported strong Q4 2025 results, surpassing analyst estimates for EPS and revenue, and provided optimistic 2026 revenue guidance.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into TransMedics Group, Inc. (TMDX) regarding potential corporate wrongdoing. The firm is encouraging shareholders of TransMedics who purchased securities before February 3, 2022, and continue to hold them, to connect with the firm to assist in the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
Zevenbergen Capital Investments LLC Boosts Stock Position in TransMedics Group, Inc. $TMDX
Zevenbergen Capital Investments LLC increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 8.4% in the fourth quarter of 2025, bringing its total holdings to 280,178 shares valued at approximately $34.08 million. Other institutional investors also adjusted their positions, with hedge funds and institutions collectively owning about 99.67% of the company's stock. Despite some insider selling and a 4.8% drop in the stock price, analysts maintain a "Moderate Buy" rating with a consensus target price of $152.33.
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into TransMedics Group, Inc. (TMDX) concerning potential corporate wrongdoing. The firm is encouraging stockholders who purchased TransMedics securities before February 3, 2022, and still hold them, to contact them to assist with the securities investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis and aims to recover investor capital and ensure corporate accountability.
TransMedics (TMDX) down 20.3% since last earnings report: Can it rebound?
This article from MSN discusses the stock performance of TransMedics (TMDX), noting a 20.3% decline since its last earnings report. It poses the question of whether the company's stock can rebound, implying an analysis of its future prospects is warranted.
TransMedics Group (TMDX) price target increased by 10.46% to 164.50
This article reports that the price target for TransMedics Group (TMDX) has been increased by 10.46%, raising it to $164.50. Additional information about the analyst who made the rating change, the previous price target, and the firm's rating on the stock is not provided.
[SCHEDULE 13G/A] TransMedics Group, Inc. Amended Passive Investment Disclosure
This SEC filing (Schedule 13G/A) for TransMedics Group Inc. (TMDX) indicates that The Vanguard Group now beneficially owns 0 shares of Common Stock, representing 0% of the class. This change is due to an internal realignment within The Vanguard Group, effective January 12, 2026, where certain subsidiaries will report beneficial ownership separately. The filing confirms that Vanguard retains rights to dividends or proceeds, and no single other person holds more than 5%.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by TransMedics Group, Inc. (TMDX). The firm encourages investors who purchased TransMedics securities before February 3, 2022, and continue to hold them, to contact them for more information and to assist with the investigation. The firm operates on a contingency fee basis for class actions.
TransMedics (TMDX) Down 20.3% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) shares have dropped 20.3% since its last earnings report, underperforming the S&P 500. Despite this, the company reported strong Q4 2025 earnings, beating estimates with revenues up 32% year-over-year, driven by increased utilization of the Organ Care System. TransMedics projects 20-25% revenue growth for 2026, with a Zacks Rank #3 (Hold) rating.
TransMedics (TMDX) Down 20.3% Since Last Earnings Report: Can It Rebound?
TransMedics (TMDX) shares have decreased by 20.3% since its last earnings report, underperforming the S&P 500. The company's Q4 2025 earnings per share and revenues surpassed Zacks Consensus Estimates, driven by increased utilization of its Organ Care System. TransMedics has also provided a positive revenue outlook for 2026, projecting 20-25% growth.
Consider Keeping TransMedics Shares in Your Portfolio at This Time
TransMedics Group, Inc. (TMDX) is positioned for growth due to advancements in its Organ Care System (OCS) technology, demonstrated by strong Q4 2025 results and progress in clinical trials like ENHANCE Heart and DENOVO Lung, with an OCS Kidney initiative also underway. Despite facing gross margin pressures from increased operational costs, the company consistently beats earnings estimates and is expanding globally and technologically. Investors are encouraged to consider holding TMDX shares, especially with its innovative OCS platform providing a competitive edge in organ transplantation.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics (TMDX) is poised for growth due to its Organ Care System (OCS) technology and strong fourth-quarter 2025 results, despite concerns about gross margin pressure. The company shows robust pipeline progress with FDA-cleared trials, and its OCS technology revolutionized organ transplantation, granting it a leadership position in a multi-billion-dollar market. However, gross margin experienced a decline due to higher clinical service costs and logistics-related expenses, leading to negative earnings estimate revisions for 2026.
TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into TransMedics Group, Inc. (NASDAQ:TMDX) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased TransMedics securities before February 3, 2022, and still hold them, to contact them to learn more and assist with the investigation. The representation of investors in class actions is done on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (NASDAQ:TMDX) securities. The investigation focuses on whether TransMedics and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before February 3, 2022, and continue to hold them. The firm encourages affected investors to contact them to assist with the investigation.
TransMedics Group Conference: CEO Outlines NOP Expansion, ENHANCE Trial Plans and Kidney Push
TransMedics Group's CEO, Waleed Hassanein, and CFO, Gerardo Hernandez-Omana, updated on the company's shift from a medical device company to a vertically integrated national transplant platform (NOP), managing nearly 30% of U.S. organ transplant volume. They discussed taking "full control" of the ENHANCE clinical trial's control arm due to competitor friction, and are actively planning for their kidney program, which could become their largest, with potential simultaneous U.S. and European clinical trial launches. The company also touched on operational updates like double-shifting for its aviation fleet and the progress of its Somerville facility.
Stocks showing improved relative strength: TransMedics Group
This article identifies TransMedics Group as a stock displaying improved relative strength. The brief mention suggests it could be an investment of interest for those tracking market movers.
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential securities claims against TransMedics Group, Inc. (TMDX) on behalf of investors who purchased shares before February 3, 2022, and continue to hold them. The firm is examining whether the company's officers and/or directors engaged in corporate wrongdoing and is encouraging affected stockholders to contact them for more information or to assist with the investigation.
TransMedics Extends Decline as Selling Pressure Builds
TransMedics (TMDX) shares have fallen, continuing a recent decline despite Stifel raising its price target to $130, citing a strengthening U.S. liver business and upcoming positive data. However, consistent insider selling by executives like CFO Gerardo Hernandez and director David Weill is contributing to the pressure, suggesting the decline is more about supply than fundamental shifts. The company's ability to execute and meet demand will be key to stabilizing investor confidence.
TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
TransMedics Group, Inc. (NASDAQ:TMDX) has received a "Moderate Buy" consensus rating from twelve brokerages, with an average 12-month price target of $152.33. Recent analyst reports vary, with some upgrading to "buy" and others downgrading to "hold" based on revised price objectives. Additionally, company insiders have recently sold shares, while institutional investors have slightly increased their holdings.
TransMedics Group (NASDAQ:TMDX) Trading Down 7.4% - What's Next?
TransMedics Group (NASDAQ:TMDX) shares dropped 7.4% on Wednesday with significantly lower trading volume than average, closing at $115.48. Despite this, Wall Street sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $152.33 from analysts. The article also notes recent insider selling by the CFO and a director, while institutional ownership is high at 99.67% with major funds increasing their positions.
17,165 Shares in TransMedics Group, Inc. $TMDX Acquired by Kensington Investment Counsel LLC
Kensington Investment Counsel LLC purchased 17,165 shares of TransMedics Group, Inc. (NASDAQ:TMDX) in Q3, valued at approximately $1.93 million, acquiring a 0.05% stake in the company. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $152.33, following target price increases from several major firms. Despite recent insider selling of 16,205 shares, insiders still hold about 7% of the stock, while institutional ownership stands at nearly 99.67%.
TransMedics Group, Inc. $TMDX Shares Bought by Fred Alger Management LLC
Fred Alger Management LLC significantly increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 303.8% in Q3, now owning 150,741 shares valued at $16.9 million. This move is part of a broader trend of institutional investors adjusting their positions in the company, which now has 99.67% of its stock owned by hedge funds and other institutional investors. The article also details recent insider stock sales and updated analyst price targets for TransMedics Group, which maintains a "Moderate Buy" rating.
Cowen Maintains Buy on TransMedics Group, Inc. (TMDX) March 2026
Cowen & Co. maintained its Buy rating on TransMedics Group, Inc. (TMDX) on March 16, 2026, citing a new product label tied to upcoming data but without issuing a new price target. The market reaction was minimal, with the stock seeing a slight increase of 0.08%. Investors are advised to view this as a reaffirmation of conviction rather than a new catalyst, with future stock performance likely contingent on the referenced data releases.
TransMedics Group, Inc. Trade Ideas — LS:A2PH5P
This article compiles several trade ideas and analyses for TransMedics Group, Inc. (TMDX) from various traders on TradingView. Discussions include technical indicators like EMA crosses, price action around all-time highs, potential breakouts, and the company's strong Q2 performance with significant revenue growth and ambitious expansion plans including acquiring additional aircraft. Recommendations range from "buy" positions with specific price targets to observations of the stock's strong relative strength and bullish flags.
TransMedics Group stock (ISIN: US89366D3075): FDA liver tailwind, kidney upside and European push reshape the 2026 story
TransMedics Group (TMDX) is entering 2026 with strong momentum driven by an FDA label expansion for its OCS Liver system, robust financial guidance indicating 20-25% revenue growth, and strategic plans for kidney program expansion and increased European presence. The company's unique integrated aviation and logistics network is seen as a competitive moat, though it introduces short-term margin pressures. The article highlights the stock's strong performance, valuation debates, and potential for upside in its integrated transplant infrastructure model.
Is TransMedics Group, Inc. (TMDX) A Good Stock To Buy Now?
TransMedics Group, Inc. (TMDX) is a medical technology company with an innovative Organ Care System (OCS) that preserves organs for transplantation. The company has a strong market position, turned profitable in early 2024, and projects significant revenue growth. Despite potential risks, its integrated technology and logistics model, along with increasing hedge fund interest, suggest substantial upside potential for long-term investors.
Kidney Expansion And Strong Outlook Might Change The Case For Investing In TransMedics Group (TMDX)
TransMedics Group (TMDX) recently exceeded Q4 expectations and provided a strong 2026 outlook, driven by continued investment in heart and lung transplant technology and plans to expand into kidney transplantation. The company's future success hinges on the progression of its ENHANCE Heart trial and navigating regulatory scrutiny of organ procurement. Despite analyst optimism, investors should consider potential risks related to regulatory changes and public perception.
TransMedics Group Stock (ISIN: US89366D3075) Surges on Strong 2026 Outlook and Kidney Expansion Plan
TransMedics Group (NASDAQ: TMDX) has seen its stock surge following robust Q4 results, an optimistic 2026 forecast, and plans to expand its Organ Care System (OCS) into kidney transplants. The company's resilience, 104% stock rise over the past year, and strategic diversification into the larger kidney transplant market are attracting significant investor interest, particularly from European investors tracking US medtech. Analysts predict substantial growth, with revenues potentially reaching $890.5 million by 2028, positioning TransMedics as a leader in organ transplantation logistics.
Kidney Expansion And Strong Outlook Might Change The Case For Investing In TransMedics Group (TMDX)
TransMedics Group (TMDX) recently announced strong Q4 results and an optimistic 2026 outlook, driven by continued investment in heart and lung transplant technology and a planned expansion into kidney transplantation. These developments, along with the FDA's full IDE approval for the ENHANCE Heart trial, could significantly reshape investor perceptions. Despite the positive news, the company still faces risks from regulatory scrutiny of organ procurement practices and DCD procedures.
Portolan Capital Management LLC Acquires New Stake in TransMedics Group, Inc. $TMDX
Portolan Capital Management LLC has purchased a new stake of 68,910 shares in TransMedics Group, Inc., valued at approximately $7.73 million. This new investment makes Portolan Capital Management LLC the owner of about 0.20% of TransMedics Group. Other institutional investors have also adjusted their holdings in the company, while some insiders have sold shares totaling over $2.35 million in the last quarter.
TransMedics (TMDX) officer Matthew Forsyth files initial Form 3 ownership
Matthew S. Forsyth, an officer of TransMedics Group, Inc. (TMDX), has filed an initial Form 3 ownership report, establishing him as a reporting insider. The filing indicates no reported purchases, sales, or other insider transactions at this time. As an officer, Forsyth is required to disclose his holdings and any future changes under SEC regulations.
Assessing TransMedics Group (TMDX) Valuation After Recent Share Price Pullback
TransMedics Group (TMDX) has experienced a recent share price pullback, but its one-year return remains strong. The company is considered undervalued with a fair value of $144.20 against its current price of $121.31, driven by anticipated growth in new organ types and next-generation product launches. However, potential risks include international expansion hurdles and competitive pressures affecting margins.
Assessing TransMedics Group (TMDX) Valuation After Recent Share Price Pullback
TransMedics Group (TMDX) has seen a recent share price pullback, with a 5.94% one-day and 13.39% seven-day decline, despite an 88.52% one-year return. Simply Wall St's narrative valuation places TMDX as 15.9% undervalued at $121.31, with a fair value of $144.20, driven by expected growth in new organ types and next-generation product launches. Investors are encouraged to look beyond the narrative and consider underlying data, potential risks like international expansion hurdles, and other investment opportunities.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by TransMedics Group, Inc. (TMDX) and its officers/directors. The firm is encouraging stockholders who purchased TransMedics securities before February 3, 2022, and still hold them, to contact them to assist in the investigation. The investigation focuses on whether there have been any breaches of fiduciary duty or other unlawful actions that have harmed investors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against TransMedics Group, Inc. (TMDX) on behalf of investors who purchased securities before February 3, 2022, and continue to hold them. The investigation focuses on whether TransMedics and its officers engaged in corporate wrongdoing. The law firm encourages affected stockholders to connect through their website to assist with the investigation, with no cost to the investors.
TransMedics group CFO Hernandez sells shares worth $1.12 million
TransMedics Group CFO Gerardo Hernandez sold approximately $1.12 million worth of company shares in early March 2026, which included two transactions at an average price of around $147. His stock sales followed his exercise of options to acquire 7,236 shares. These transactions occurred as the company reported strong Q4 2025 earnings, significantly beating analyst expectations, and provided optimistic revenue guidance for 2026, leading to increased price targets from analysts like Needham and Stifel, despite some mixed factors.
(TMDX) and the Role of Price-Sensitive Allocations
This article provides an analysis of Transmedics Group Inc. (NASDAQ: TMDX), highlighting a weak near-term sentiment but potential for shifts in mid and long-term outlook. It details specific AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging. The analysis identifies key support and resistance levels across multiple timeframes, suggesting a significant risk-reward setup.
Fieldview Capital Management LLC Acquires New Position in TransMedics Group, Inc. $TMDX
Fieldview Capital Management LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 15,291 shares valued at approximately $1.72 million in the third quarter. Other institutional investors like Marshall Wace LLP, Zevenbergen Capital Investments LLC, and Goldman Sachs Group Inc. also made significant moves in the company's stock. Despite some recent insider selling totaling $2.35 million, corporate insiders still hold about 7% of the company, and analysts have set a consensus target price of $152.33 with a "Moderate Buy" rating.
TransMedics Group (TMDX) Analyst Ratings Update: Stifel Raises P
Stifel maintained a 'Hold' rating on TransMedics Group (TMDX) but raised its price target from $115 to $130, a 13.04% increase. This follows similar price target increases from other analysts including Needham, Evercore ISI Group, Piper Sandler, Oppenheimer, and JP Morgan in late February 2026. The average one-year price target from 11 analysts is now $161.27, suggesting a 24.43% upside from the current price, with a consensus "Outperform" rating from 14 brokerage firms.
TransMedics: Numb Reaction To Extraordinary Fundamentals (NASDAQ:TMDX)
TransMedics (TMDX) has transformed into a profitable growth company with strong fundamentals, reducing historical stock volatility. The company reported robust Q4 results, surpassing revenue and earnings estimates with 32% year-over-year growth and expanded operating margins. Management projects 20-25% revenue growth for 2026, driven by Liver segment dominance and potential from Heart, Lung, and Kidney programs, leading the author to reiterate a "Buy" rating with a $160 price target.
TransMedics Group (NASDAQ:TMDX) Price Target Raised to $130.00
Stifel Nicolaus has raised its price target for TransMedics Group (NASDAQ:TMDX) to $130.00 from $115.00, while maintaining a "hold" rating. The company has a consensus "Moderate Buy" rating with an average target price of $152.33 from a range of firms. Despite the updated price target, the stock was trading down 7.3% and insider selling events, including the CFO selling over $1 million in shares, have been reported.
12 Best Under-the-Radar Stocks to Buy According to Hedge Funds
This article highlights TransMedics Group, Inc. (NASDAQ: TMDX) as one of the best under-the-radar stocks, according to hedge funds. Several analysts, including Baird, Oppenheimer, and Piper Sandler, recently raised their price targets and reiterated Outperform/Overweight ratings for TMDX following strong fourth-quarter results and positive 2026 outlook. The company is recognized for its medical technology in organ transplantation, particularly for heart, lung, and potentially kidney failure.
4 Top Stocks Long-Term Investors Should Buy in March
This article recommends four top stocks for long-term investors to buy in March 2026: Axon Enterprise (AXON), Vertiv (VRT), TransMedics Group (TMDX), and Fair Isaac (FICO). These companies are highlighted for their strong market positions, double-digit growth, and critical roles in their respective industries, with each presenting robust financial performance and significant future potential. The author emphasizes that these are not speculative plays but established businesses with solid fundamentals.
Insider Sell: Stephanie Lovell Sells Shares of TransMedics Group Inc (TMDX)
Stephanie Lovell, a Director at TransMedics Group Inc (TMDX), sold 1,193 shares of the company on March 4, 2026. This transaction reduces her total holdings to 2,866 shares. The article notes that TransMedics Group is considered modestly undervalued with a price-to-GF-Value ratio of 0.86, trading at $149.62 against a GF Value of $174.51.
TransMedics Group (NASDAQ:TMDX) Director David Weill Sells 3,571 Shares
TransMedics Group (NASDAQ:TMDX) Director David Weill sold 3,571 shares of the company's stock on March 4th for a total of $524,294.22, reducing his holdings by 22.74%. Following the sale, the stock dropped $10.27 to $129.80, trading below its 50-day moving average, though it still has a consensus "Moderate Buy" rating and institutional investment has increased. The company specializes in organ preservation and transport systems for transplantation.
Stephanie Lovell Sells 1,193 Shares of TransMedics Group (NASDAQ:TMDX) Stock
Stephanie Lovell, a Director at TransMedics Group (NASDAQ:TMDX), sold 1,193 shares of the company's stock on March 4th for a total of $178,496.66. This transaction reduced her holding by 29.39% to 2,866 shares. Following the sale, TransMedics' stock fell by 7.3%, although analysts maintain a "Moderate Buy" rating with an average price target of $150.67.
TransMedics Group Inc. (NASDAQ:TMDX) Combines Strong Earnings Momentum with Bullish Technical Setup
TransMedics Group Inc. (NASDAQ:TMDX) is highlighted as an attractive investment opportunity due to its strong earnings momentum and bullish technical setup. The company demonstrates significant EPS growth, consistent earnings surprises, and increasing profitability, alongside a favorable chart formation indicative of institutional buying and a potential breakout. This combination of robust fundamentals and positive price action suggests a well-timed entry point for growth and momentum investors.
A Look At TransMedics Group (TMDX) Valuation After Strong Results And Optimistic Revenue Guidance
TransMedics Group (TMDX) has reported strong Q4 and full-year 2025 results with optimistic 2026 revenue guidance, leading to a significant 118.95% one-year shareholder return. While one narrative suggests the stock is 2.4% overvalued at $144.20, Simply Wall St's DCF model indicates it could be 38.5% undervalued with a fair value of $240.24. The article advises investors to conduct their own review and explore other investment opportunities using available tools.
